The top three U.S. M&A deals of 2023 by deal value include, Exxon (XOM) acquiring Pioneer (PXD), Chevron's (CVX) acquisition of Hess (HES), and Pfizer (PFE) acquiring Seagen (SGEN), according to Dealogic. The KPMG 2024 M&A Outlook Survey found that 7 in 10 dealmakers are working currently on deals and 2 out of 3 said 2024 will be more active. KPMG Head of Deal Advisory & Strategy Carole Streicher joins Yahoo Finance Live to discuss the survey's findings and what 2024 will look like for mergers a...

Astellas Pharma Inc. (TSE:4503, President and CEO: Naoki Okamura, "Astellas") and Pfizer Inc. (NYSE: PFE) today announced that on December 15, 2023 the U.S. Food and Drug Administration (FDA) has approved PADCEV® (enfortumab vedotin-ejfv, an antibody-drug conjugate [ADC]) with KEYTRUDA® (pembrolizumab, a PD-1 inhibitor) for the treatment of adult patients with locally advanced or metastatic urothelial cancer (la/mUC). This combination is the first approved to offer an alternative to platinum-con

The Biden administration is increasingly focused on finding ways to lower drug prices, putting the drug industry in a three-way battle to defend its ecosystem.

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Illumina (ILMN) seeks to resolve it's battle with EU regulators regarding acquisition of biotech company Grail. Earlier this year, Illumina received a $476 million fine from EU authorities over the deal. It comes as Pfizer (PFE) says it has received all the necessary regulatory approvals for its acquisition of Seagen (SGEN). Yahoo Finance's Anjalee Khemlani breaks down the biggest pharma stories of the day in the video above. For more expert insight and the latest market action, click here to wa...

BOTHELL, Wash., December 11, 2023--Seagen Inc. (NASDAQ: SGEN) today announced that clinically meaningful progression-free survival (PFS), a secondary endpoint, was observed in a Phase 2 study evaluating the antibody-drug conjugate (ADC) ADCETRIS® (brentuximab vedotin) in combination with the PD-1 inhibitor nivolumab and standard chemotherapy agents doxorubicin and dacarbazine (AN+AD) as first-line treatment for early and advanced stage classical Hodgkin lymphoma (cHL). This is the first time 12-

BOTHELL, Wash., December 06, 2023--Seagen Inc. (Nasdaq: SGEN) today announced data from the Phase 3 HER2CLIMB-02 clinical trial of TUKYSA® (tucatinib) in combination with the antibody-drug conjugate ado-trastuzumab emtansine (Kadcyla®). The combination showed a statistically significant improvement in progression-free survival (PFS), the study’s primary endpoint, in patients with unresectable locally advanced or metastatic human epidermal growth factor receptor 2-positive (HER2-positive) breast

Seattle Genetics (SGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

BOTHELL, Wash. & TOKYO, November 30, 2023--Seagen Inc. (Nasdaq: SGEN) and Astellas Pharma Inc. (TSE:4503) today announced that on November 30, 2023 the U.S. Food and Drug Administration (FDA) accepted for priority review a supplemental Biologics License Application (sBLA) for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) as a combination therapy for the treatment of adult patients with locally advanced or metastatic urothelial cancer (la/mUC), a form of bladder cancer that has

BOTHELL, Wash., November 03, 2023--Seagen Inc. (NASDAQ: SGEN) today announced the first presentation of data evaluating ADCETRIS® (brentuximab vedotin) in combination with an anti-PD-1 checkpoint inhibitor in non-small cell lung cancer (NSCLC) and melanoma, and shared preclinical data for an investigational CD30-directed antibody-drug conjugate (ADC) that uses a novel tripeptide linker. The studies were presented at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting, taking place